Did Indivior beat or miss consensus estimates last quarter?

What were the key takeaways from Indivior’s earnings call?

What were the key takeaways from Indivior's earnings call?

What is Indivior's latest dividend and current dividend yield?

What does Indivior do and what are its main business segments?

What is Indivior's gross profit margin?

What is the revenue and EPS growth rate for Indivior year over year?

What factors drove the changes in Indivior's revenue and profit?

- **Record Financial Performance**: 2025 total net revenue $1.24B (+4% YoY), adjusted EBITDA $428M (+20% YoY). 2026 guidance: adjusted EBITDA $535-$575M (+30%), SUBLOCADE net revenue +8%.
- **Share Repurchase Program**: $400M authorized to return value to shareholders, complementing debt management.
- **SUBLOCADE Growth**: Target mid-teens dispense unit growth (vs. 7% in 2025), driven by DTC campaign success (60% search volume increase) and commercial execution improvements.
- **Strategic Expansion**: Seeking commercial-stage assets with >$200M peak sales, focusing on differentiated therapies with durable runways beyond 2030.

**【CEO Summary Section】**
- **2025 Financial Highlights**: Total net revenue of $1.24 billion (+4% YoY), SUBLOCADE net revenue $856 million (+13% YoY), adjusted EBITDA $428 million (+20% YoY). Completed phase 1 of Indivior Action Agenda, simplifying operations to cap 2026 operating expenses at $450 million.
- **2026 Growth Strategy**: Target mid-teens SUBLOCADE dispense unit growth (vs. 7% in 2025), 8% SUBLOCADE net revenue growth, and 30% adjusted EBITDA expansion to $550 million. Launched $400 million share repurchase program.
- **Long-Term Vision**: Pursue phase 3 business development for commercial-stage assets with >$200M peak sales potential, focusing on differentiated therapies with durable runways.

**【CCO Commercial Update】**
- **SUBLOCADE Momentum**: Q4 2025 dispense units +12% YoY, new patient starts +25% YoY, active prescribers +14% YoY. Direct-to-consumer campaign drove 60% increase in online searches and 70% growth in treatment provider tool usage.
- **Market Position**: SUBLOCADE maintains mid-70% category share, with 475,000+ patients treated. Differentiated by 12 patents (2031-2038) and rapid initiation label.
- **Policy Advocacy**: Engaging on pharmacy benefit carve-outs and bundled payment structures to reduce access barriers.

**【CFO Financial Commentary】**
- **2025 Financials**: GAAP net loss $1.1 billion (includes DOJ settlement), non-GAAP operating expenses $622 million (-5% YoY). 2026 guidance: total net revenue $1.125-$1.195 billion, adjusted EBITDA $535-$575 million, cash flow from operations >$300 million.
- **Capital Allocation**: Prioritize debt management, share buybacks, and strategic acquisitions. 2025 cash flow from operations exceeded $200 million despite one-time expenses.
- **R&D Update**: Two phase II trials (INDV-6001, INDV-4001) nearing readouts; decisions to advance to phase III will depend on manufacturing, payer validation, and trial design feasibility.

**【Q&A Highlights】**
- **Market Growth**: CEO estimates LAI buprenorphine penetration could reach 20%-30%, citing schizophrenia analogs. CCO notes Q4 2025 category growth ~18%.
- **Share Dynamics**: SUBLOCADE maintains mid-70% new patient share, but focus on absolute volume growth over market share.
- **Capital Deployment**: CFO emphasizes balance between buybacks, debt reduction, and M&A. Share repurchase program opportunistic, conditioned on stock price vs. intrinsic value.
- **CJS Contribution**: CCO highlights criminal justice system as rebase opportunity, but overall growth driven by broader category leadership.
- **R&D Risk**: CEO notes phase II decisions could impact 2026 R&D spend, but core focus remains on SUBLOCADE and operational efficiency.

Indivior PLC (INDV) Q4 2025 Earnings Call Transcript

- **Revenue Growth**: SUBLOCADE up 15% YoY, total net revenue +2% YoY, with 2025 guidance raised to +10% SUBLOCADE growth at midpoint.
- **Cost Efficiency**: $150M annual OpEx savings starting 2026, 2026 OpEx capped at $450M, and 32% headcount reduction.
- **Strategic Investments**: New DTC campaign launched, with focus on U.S. LAI penetration (~8% share vs. 20-25% analogs).
- **Cash Position**: $473M cash as of Q3, with strong cash flow generation and 2026 acceleration of profitability.
- **Phase Transition**: Moving to Phase II, 'Accelerate,' with 2026 financial guidance to be announced in January.

**【CEO Summary Section】**
- Delivered strong Q3 performance with 15% year-over-year growth in SUBLOCADE net revenue, driven by improved commercial execution and price stability in SUBOXONE Film.
- Raised 2025 full-year guidance: total net revenue expected to grow vs. 2024 at midpoint (SUBLOCADE +10%), and adjusted EBITDA up 15%.
- Announced $150 million annual OpEx savings starting in 2026, with 2026 OpEx budget capped at $450 million.
- Launched new direct-to-consumer (DTC) campaign, 'Move Forward in Recovery,' to drive awareness and prescribing momentum.
- Transitioning to Phase II, 'Accelerate,' on January 1, 2026, with focus on maximizing SUBLOCADE growth and cash flow generation.

**【CCO Commercial Execution】**
- SUBLOCADE dispense volume grew 8% YoY and 3% QoQ, with category share stable at ~75%.
- Key drivers: enhanced field force messaging, rapid induction label update (day 8 second dose), and 11% growth in active prescribers.
- New DTC campaign emphasizes patient dignity and recovery, with omnichannel reach (TV, digital, in-office materials).
- Commercial focus on U.S. expansion, with 2026 investments to accelerate penetration in the LAI category (~8% current share vs. 20-25% analogs).

**【CFO Financial Performance】**
- Q3 total net revenue: $314 million (+2% YoY), SUBLOCADE: $219 million (+15% YoY), adjusted EBITDA: $120 million (+14% YoY).
- OpEx: $145 million (-3% YoY), with R&D down 11% and SG&A flat due to restructuring.
- 2025 guidance: total net revenue $1.18-1.22 billion, SUBLOCADE $825-845 million, adjusted EBITDA $400-420 million.
- Cash position: $473 million (up $200 million YoY), with $200 million+ cash flow from operations expected for 2025.
- 2026 OpEx savings: $150 million from headcount reduction (32%), non-essential spend cuts, and Rest of World optimization.

**【Q&A Highlights】**
- **OpEx Breakdown**: $150M savings = 50% labor cuts, 30% non-essential spend, 10% OPVEE discontinuation, 10% ROW optimization.
- **SG&A Target**: No specific peer benchmark; focus on essential U.S. investments, with 2026 SG&A ~$510-520 million.
- **R&D Outlook**: Streamlined pipeline with Phase II assets; no immediate Phase III plans, but保留 flexibility.
- **2026 Growth**: SUBLOCADE demand indicators positive, with DTC campaign and commercial execution improvements expected to drive momentum.
- **Rest of World**: 77% of ROW revenue from key markets (Australia, Canada, France, Germany), with cost reductions and focus on core assets.


Indivior PLC (INDV) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 net revenue $302M (+1% YoY), SUBLOCADE up 9% to $209M, driving 2025 guidance raise to $1.03-1.08B.
- **Strategic Roadmap**: 3-phase Indivior Action Agenda to simplify, accelerate, and acquire growth, with Phase 1 execution underway.
- **Profitability Boost**: Adjusted EBITDA guidance up 20% to $275-300M, reflecting cost savings and SUBLOCADE momentum.
- **Commercial Focus**: Targeting 60% commercial covered lives (vs. 25% SUBLOCADE volume) through digital campaigns and specialty pharmacy improvements.
- **Cost Efficiency**: Significant cost reductions expected, with full-year impact in 2026.

**【CEO Summary Section】**
- **Record Performance**: Q2 2025 net revenue reached $302 million, driven by 9% YoY growth in SUBLOCADE to $209 million and stable pricing of SUBOXONE Film.
- **Indivior Action Agenda**: 3-phase plan to simplify operations and accelerate growth:
  - **Phase 1 (2025)**: Improve U.S. commercial execution, streamline operations (e.g., delist from LSE), and prepare for Phase 2.
  - **Phase 2 (2026)**: Accelerate SUBLOCADE growth and profitability through optimized go-forward model.
  - **Phase 3 (2026+)**: Acquire commercial-stage assets to diversify growth.
- **Cost Efficiency**: Raised 2025 adjusted EBITDA guidance to $275-300 million (20% midpoint increase) and expects significant cost savings post-simplification.

**【CFO Financial Commentary】**
- **Top Line**: Total net revenue guidance raised to $1.03-1.08 billion (vs. prior $1.00-1.05 billion), with SUBLOCADE at $765-785 million (+3% YoY midpoint).
- **Profitability**: Adjusted EBITDA up 20% YoY midpoint to $275-300 million, driven by SUBLOCADE growth and cost control.
- **Balance Sheet**: Ended Q2 with $538 million in cash, up from $347 million at year-end, supporting Phase 1 execution.

**【Q&A Key Highlights】**
- **Commercial vs. Medicaid Focus**: 60% of covered lives are commercial, but SUBLOCADE volume is only 25%. Strategy includes digital media, DTC campaigns, and specialty pharmacy optimization to increase commercial penetration.
- **Criminal Justice System**: Post-Federal Bureau of Prisons formulary loss, SUBLOCADE is stabilizing and sees opportunity for growth in this channel.
- **R&D Prioritization**: Reprioritized to Phase 2 OUD assets (INDV-6001, 2000), with Phase 3 enrollment expected by end-2025.
- **Cost Savings**: CEO emphasizes 'meaningful and significant' cost reductions, with full-year benefits expected in 2026.
- **Medicaid Environment**: Stable with no near-term headwinds; long-acting injectable (LAI) penetration at ~8% provides ample growth opportunity.

Indivior PLC (INDV) Q2 2025 Earnings Call Transcript

- **Revenue decline**: 6% YoY drop due to generic competition and PERSERIS exit.
- **SUBLOCADE resilience**: 70% new patient share in justice system, stable dual prescriber share at 65%.
- **Cost savings**: $100M+ savings reinvested, $50M to SUBLOCADE growth.
- **H2 outlook**: SUBLOCADE net revenue improvement expected from label updates and marketing.
- **Financial strength**: $400M cash, non-GAAP gross margin 80-85%.
- **Litigation**: Settlement progress consistent with accrual; no major updates.

**【CEO Summary Section】**
- Total net revenue declined 6% YoY due to generic film competition and PERSERIS discontinuation.
- SUBLOCADE net revenue down 2% YoY, with U.S. performance impacted by justice system funding challenges but OHS channel growth offsetting.
- 14% YoY increase in 12-month U.S. patient count to ~170,700.
- SUBLOCADE maintains ~70% new patient share in justice system, stable among dual prescribers at ~65%.
- $100M+ cost savings reinvested: $50M into SUBLOCADE, $50M+ to bottom line.
- Full-year guidance reaffirmed, with SUBLOCADE net revenue expected to improve H2.

**【CFO Financial Commentary】**
- Q1 2025 total net revenue $266M (-6% YoY), U.S. down 8%, RoW +3% (1% CC).
- SUBLOCADE U.S. net revenue -9% QoQ due to destocking and justice system funding issues.
- Gross margin 83% (-200bps YoY) due to one-time manufacturing benefits in Q1 2024.
- Non-GAAP adj. operating income $59M (-10% YoY), EPS $0.41 (-2% YoY).
- Cash balance $400M (higher than expected due to delayed Medicaid billing).
- 2025 non-GAAP gross margin guidance: low to mid-80%.

**【Q&A Key Highlights】**
- **SUBLOCADE Growth**: Expect H2 improvement from label updates (rapid induction, alternate injection sites, day 8 dose) and marketing investments. New patient share stable at ~70% in justice system.
- **Justice System Funding**: Short-term challenges (budget reallocations, abatement funds) expected to ease with 19 states' Medicaid 1115 waivers approved.
- **SUBOXONE Film**: Share down 3pts YoY, price erosion continues with 4 generics. No impact from Teva launch yet.
- **OPVEE**: BARDA order $8M, full-year net revenue $10-15M. Real-world evidence generation key to adoption.
- **Litigation**: Motion to dismiss U.S. shareholder claims granted; progress on opioid MDL settlement consistent with accrual.
- **Leadership Transition**: Incoming CEO Joe to focus on SUBLOCADE growth and pipeline reinvestment.

Indivior PLC (INDV) Q1 2025 Earnings Conference Call Transcript

- **SUBLOCADE Growth**: 20% YoY net revenue growth in 2024, treating 171,000 patients (25% increase from 2023). 2025 guidance assumes stabilization at $725-765 million amid CGS funding challenges.
- **Cost Efficiency**: $100+ million annual cost cuts, delivering $50 million 2024 savings. 2025 operating expenses to decline >$50 million.
- **Risk Factors**: 55% decline in SUBOXONE Film net revenue in 2025 due to generic competition; CGS channel down 30-35% as justice systems shift to orals.
- **Long-Term Vision**: SUBLOCADE peak net revenue target of >$1.5 billion remains intact, with 30% of OUD patients estimated to benefit from LAIs (currently 8% penetrated).

**【CEO Summary Section】**
- **2024 Performance Highlights**: Total net revenue grew 9% to $1.06 billion, driven by SUBLOCADE's 20% year-over-year growth. SUBLOCADE ended the year with 171,000 patients, up 25% from 2023.
- **Challenges Addressed**: Discontinued PERSERIS due to profitability concerns and implemented $100+ million annual cost reductions, saving $50 million in 2024.
- **2025 Outlook**: Guidance for $955 million to $1.25 billion net revenue reflects 55% decline in SUBOXONE Film and stabilization of SUBLOCADE at $725-765 million. Focus on reinvesting in SUBLOCADE and Phase 2 pipeline assets.

**【CFO Financial Commentary】**
- **2024 Financials**: Adjusted net income of $312 million ($1.66 per share), up 16%. Gross margin remained stable at 83%, with SG&A up 6% due to commercial investments.
- **2025 Guidance**: Operating expenses expected to decline >$50 million, with R&D at $85-90 million. Gross margin to improve post-2026 as SUBLOCADE mix grows and Raleigh manufacturing ramps up.
- **Liquidity**: Ended 2024 with $347 million cash, supported by $400 million debt facility refinanced in Q4.

**【Q&A Key Takeaways】**
- **CGS Channel Dynamics**: 30-35% decline in 2025 due to funding gaps, but long-term opportunity remains with 60% of OUD patients interacting with justice systems.
- **Market Share**: Cohort analysis shows 65% share among dual-LAI prescribers, with 71% of new starts on SUBLOCADE in Q4.
- **SUBOXONE Film Pricing**: 55% decline expected in 2025 due to generic competition, with potential 5th entrant accelerating erosion.
- **Capital Allocation**: Prioritizing SUBLOCADE and pipeline, no plans for M&A or shareholder returns in 2025.

Actual	0.39	0.34	0.43	0.37	0.44	0.54	0.32	0.41	0.51	0.72	0.82
Forecast	0.22	0.34	0.3	0.415	0.4033	0.4067	0.2225	0.2333	0.26	0.4117	0.674
Surprise	+77.27%	0.00%	+43.33%	-10.84%	+9.10%	+32.78%	+43.82%	+75.74%	+96.15%	+74.88%	+21.66%

Actual	276.00M	271.00M	293.00M	284.00M	299.00M	307.00M	298.00M	266.00M	302.00M	314.00M	358.00M
Forecast	255.00M	270.50M	276.00M	299.75M	289.70M	302.97M	259.78M	240.13M	244.50M	261.92M	305.62M
Surprise	+8.24%	+0.18%	+6.16%	-5.25%	+3.21%	+1.33%	+14.71%	+10.77%	+23.52%	+19.89%	+17.14%

INDV

INDV fundamentals

INDV Q4 2025 Earnings

Earnings Call

You can ask Aime

INDV

INDV fundamentals

INDV Q4 2025 Earnings

Earnings Call

INDV Earnings Call Summary for Q4/20258:00 AM on Feb 26, 2026

INDV Earnings Call Summary for Q3/20258:00 AM on Oct 30, 2025

INDV Earnings Call Summary for Q2/20257:00 AM on Jul 31, 2025

INDV Earnings Call Summary for Q1/20258:00 AM on Apr 24, 2025

INDV Earnings Call Summary for Q4/20248:00 AM on Feb 20, 2025

You can ask Aime